These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26165081)

  • 21. Can dietary integrators provide a clinical benefit in the treatment of functional dyspepsia? results from a prospective study with TUBES Gastro.
    Molteni M
    Minerva Gastroenterol Dietol; 2014 Jun; 60(2):105-12. PubMed ID: 24780944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Update on current care guidelines. A current care guideline: recurrent upper gastrointestinal symptoms].
    Paikka N
    Duodecim; 2012; 128(22):2376-7. PubMed ID: 23342484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of functional dyspepsia.
    Lee KJ; Kindt S; Tack J
    Best Pract Res Clin Gastroenterol; 2004 Aug; 18(4):707-16. PubMed ID: 15324709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of duodenal lipids on gastric sensitivity and relaxation in patients with ulcer-like and dysmotility-like dyspepsia.
    Björnsson E; Sjöberg J; Ringström G; Norström M; Simrén M; Abrahamsson H
    Digestion; 2003; 67(4):209-17. PubMed ID: 12966228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?).
    Stanghellini V; Frisoni C
    Am J Gastroenterol; 2010 Dec; 105(12):2632-4. PubMed ID: 21131930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a muscarinic M3 receptor agonist on gastric motility.
    Chiba T; Kudara N; Sato M; Inomata M; Orii S; Suzuki K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2039-41. PubMed ID: 17914991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel concepts in the pathophysiology and treatment of functional dyspepsia.
    Wauters L; Talley NJ; Walker MM; Tack J; Vanuytsel T
    Gut; 2020 Mar; 69(3):591-600. PubMed ID: 31784469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ghrelin: a gut hormonal basis of motility regulation and functional dyspepsia.
    Ogiso K; Asakawa A; Amitani H; Inui A
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():67-72. PubMed ID: 21443713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Approaches to Diagnosis and Treatment of Functional Dyspepsia.
    Tomita T; Oshima T; Miwa H
    Curr Gastroenterol Rep; 2018 Oct; 20(12):55. PubMed ID: 30338390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current understanding of pathogenesis of functional dyspepsia.
    Miwa H; Watari J; Fukui H; Oshima T; Tomita T; Sakurai J; Kondo T; Matsumoto T
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():53-60. PubMed ID: 21443711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duodenal inflammation: an emerging target for functional dyspepsia?
    Wauters L; Burns G; Ceulemans M; Walker MM; Vanuytsel T; Keely S; Talley NJ
    Expert Opin Ther Targets; 2020 Jun; 24(6):511-523. PubMed ID: 32249629
    [No Abstract]   [Full Text] [Related]  

  • 32. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification.
    Lee KJ; Kim JH; Cho SW
    J Gastroenterol Hepatol; 2006 Mar; 21(3):515-20. PubMed ID: 16638092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of drug therapy for functional dyspepsia.
    Chen SL
    J Dig Dis; 2013 Dec; 14(12):623-5. PubMed ID: 23957752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of ghrelin in patients with functional dyspepsia and its potential clinical relevance (Review).
    Yagi T; Asakawa A; Ueda H; Miyawaki S; Inui A
    Int J Mol Med; 2013 Sep; 32(3):523-31. PubMed ID: 23778458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent insights into digestive motility in functional dyspepsia.
    Mizuta Y; Shikuwa S; Isomoto H; Mishima R; Akazawa Y; Masuda J; Omagari K; Takeshima F; Kohno S
    J Gastroenterol; 2006 Nov; 41(11):1025-40. PubMed ID: 17160514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effect of the selective serotonin 5-HT₃ receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats.
    Nakata-Fukuda M; Hirata T; Keto Y; Yamano M; Yokoyama T; Uchiyama Y
    Eur J Pharmacol; 2014 May; 731():88-92. PubMed ID: 24632457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastric emptying and antral motility parameters in children with functional dyspepsia: association with symptom severity.
    Devanarayana NM; Rajindrajith S; Perera MS; Nishanthanie SW; Benninga MA
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1161-6. PubMed ID: 23517336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the evaluation and management of functional dyspepsia.
    Loyd RA; McClellan DA
    Am Fam Physician; 2011 Mar; 83(5):547-52. PubMed ID: 21391521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton pump inhibitors for dyspepsia.
    Vakil N
    Dig Dis; 2008; 26(3):215-7. PubMed ID: 18463438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
    Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Sander P; Lühmann R
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1279-89. PubMed ID: 22486552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.